Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Belumosudil→

Belumosudil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
911417-87-3
Molecular formula
C26H24N6O2
Molecular weight
452.5 g/mol
Drug class
Rho-associated coiled-coil containing protein kinase (ROCK) inhibitorpreferential ROCK2 inhibitor
Mechanism of action
Inhibits ROCK2 more potently than ROCK1. Inhibition modulates pro-inflammatory responses through effects on STAT3/STAT5 phosphorylation and Th17/Treg balance and reduces aberrant profibrotic signalling; these actions are relevant to chronic graft-versus-host disease.
Indications / reported uses
  • Treatment of adults and paediatric patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy under the current US product label

Sources: NLM DailyMed — REZUROCK (belumosudil), updated 3 Feb 2026 · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor; preferential ROCK2 inhibitor

Mechanism of action

Inhibits ROCK2 more potently than ROCK1. Inhibition modulates pro-inflammatory responses through effects on STAT3/STAT5 phosphorylation and Th17/Treg balance and reduces aberrant profibrotic signalling; these actions are relevant to chronic graft-versus-host disease.

General use cases

  • Treatment of adults and paediatric patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy under the current US product label

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Belumosudil Environmental Risk Assessment (ERA) (the Belumosudil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.